Personlized dendritic cell vaccine increases survival in patients with deadly brain cancer

A dendritic cell vaccine personalized for each individual based on the patient's own tumor may increase median survival time in those with a deadly form of brain cancer called glioblastoma, an early phase study at UCLA's Jonsson Comprehensive Cancer Center has found.

Read the whole article on Physorg

More from Physorg